1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis

Background

Chemotherapy alone has limited efficacy in treating advanced pancreatic cancer (APC). The addition of nimotuzumab (nimo) to gemcitabine had been shown to be more effective in our previous studies: the progression-free survival (PFS) was up to 5.1 months, 1.5 months longer than gemcitabine alone for 1st line treatment of APC, but its efficacy and safety in combination with other chemotherapy regimens are unknown.

Methods

In this study, patients with APC were treated with standard of care (routine chemotherapy) combined with or without nimo in a real-world data setting. Demographic and clinical data were collected from electronic medical records of First Affiliated Hospital of Xi’an Jiaotong University from April 2018 to May 2023. The primary efficacy endpoint was progression-free survival (PFS).

Results

We identified 282 APC patients, of which 36.8% received nimo combined with routine chemotherapy. After 1:1 propensity score matching (PSM), we created 65 pairs patients (median age was 62 years, range, 55-69) who received routine chemotherapy with or without nimo as first-line treatment. Among them, 55 pairs were treated with albumin paclitaxel-gemcitabine (AG), 3 pairs with gemcitabine-tegafur (GS) and 7 pairs with others. The median dosage of nimo was 400mg weekly. Up to May 2023, the median follow-up time was beyond 24 months. Survival analysis showed that nimo was associated with longer PFS (10.9 months vs 9.1 months; p<0.05, HR=0.5(95%CI, 0.29-0.88) after matching), but the OS was not evaluated due to the missing date of death. No grade 3 or above toxicities were observed.

Conclusions

Gemcitabine-based combination chemotherapy (eg, AG regimen, GS regimen) were commonly used as first-line treatment for APC in China. The addition of nimotuzumab to combination chemotherapy was a strong regimen and found to prolong the survival time for APC, with a manageable safety profile.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.